213 results about "Cytoskeleton" patented technology

The invention provides a method for effecting the trans-differentiation of a somatic cell, i.e., the conversion of a somatic cell of one cell type into a somatic cell of a different cell type. The method is practiced by culturing a somatic cell in the presence of at least one agent selected from the group consisting of (a) cytoskeletal inhibitors and (b) inhibitors of acetylation, and (c) inhibitors of methylation, and also culturing the cell in the presence of agents or conditions that induce differentiation to a different cell type. The method is useful for producing histocompatible cells for cell therapy.

A red blood cell storage composition includes a composition of red blood cells and biochemistry altering reagents, the biochemistry altering reagents being present at a concentration so as to reduce the percent hemolysis of the red blood cells during the freeze-thaw cycle below that of the percent hemolysis of the red blood cells in the absence the biochemistry altering reagents. The red blood cell storage composition preferably includes reagents selected from: modifiers of glycolytic/metabolic components, modifiers of antioxidant potential, effectors of intracellular ionic distribution, modifiers of membrane fluidity, modifiers of cytoskeletal structure, effectors of the cyclooxygenase second messenger pathway, effectors of the lipoxygenase second messenger pathway, effectors of the hexose monophosphate second messenger pathway, effectors of the phosphorylation second messenger pathway, modifiers of specific messenger molecules, and combinations thereof.

The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering an effective amount of a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification.

The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification.

The invention further provides a kit. The kit comprises a diketopiperazine, a prodrug of a diketopiperazine or a pharmaceutically-acceptable salt of either of them to the animal, wherein the diketopiperazine has the formula set forth in the specification.

The invention discloses a three-dimensional large-aperture nanoscale fibrous scaffold and a method for preparing the same. The average diameter of fibers in the scaffold is about 1 nanometer to 900 nanometers, the voidage is about 50%-98%, the scaffold is of a three-dimensional structure, and the thickness of the scaffold is 0.01 micrometer to 10 centimeters. The method includes the following steps of dissolving biodegradable polyester and additives into organic solvent to prepare spinning solution. An electrostatic spinning process is used for spinning the spinning solution to obtain nanoscale/submicron-order fibrofelt. The fibrofelt is soaked in solvent within 48 hours after being spun, is pre-frozen at first, and then is frozen and dried, so that the three-dimensional fibrous scaffold with mutually communicated large holes is obtained. The three-dimensional tissue engineering scaffold material with the communicated large holes is prepared, the structures of the internal holes are uniform, and the three-dimensional large-aperture nanscale fibrous scaffold can be used as a tissue engineering cytoskeleton for bones, cartilages, blood vessels, hearts, nerves and the like, and is suitable for growth of various cells.

The invention discloses an aggregated white blood cell segmentation counting system. The system comprises an image acquisition module for dyeing white blood cells in a blood sample, dissolving red blood cells in the blood sample by using red blood cell lysate and acquiring a white blood cell image, an image preprocessing module used for performing image background removal on the white blood cellimage and obtaining an optimal segmentation threshold by using a maximum inter-class variance method and roughly segmenting a white blood cell region, an aggregated cell determination module used forobtaining a coarse segmentation image according to the rough segmentation of the white blood cell region, setting a discriminant function of a cell area and obtaining a multi-cell aggregation region,and an aggregated cell segmentation counting module used for extracting a cytoskeleton in each aggregation region and a gray curve at the cytoskeleton by using a morphological refinement method. According to the invention, by analyzing the gray scale characteristics of various white blood cell areas under a low power microscope, an adaptive threshold function is constructed, while a white blood cell count is obtained, the number of oxyphil cells is obtained, the cells in the aggregation region are quickly and accurately divided and counted, the method is quick and simple and is easy to implement.

The invention belongs to the field of biomedicine and particularly discloses the application of gold nanocluster in preparation of a drug for treating tumors. Experimental study discovers that the gold nanocluster can enter cells by virtue of receptor-mediated endocytosis, form endosome and fuse with lysosome so as to deposit in the lysosome. Under light conditions, a photo chemical reaction is carried out on the surface of the gold nanocluster, production of reactive oxide species (ROS) is triggered, apoptosis is initiated, and the ROS can further attack cytoskeleton to cause cytoskeleton fracture and functional damage. The invention firstly proposes that the gold nanocluster can serve as a novel nano-drug to be used for treatment of tumors. As the nano-drug, the gold nanocluster is excellent in biocompatibility and high in safety. As an inert metal, the gold has excellent biocompatibility, and small interference on normal physiological activities of organisms/cells and low toxicity;the gold nanocluster has an effect of killing the tumors under specified conditions only, and is high in using safety.

The invention provides a nerve conduit. The nerve conduit is characterized by comprising an inner layer, an outer layer and a cavity; the outer surface of the inner layer is wrapped with the outer layer; the cavity is formed between the inner layer and the outer layer; the inner layer is a hydrophilic cytoskeleton layer manufactured by the electrostatic spinning method; the outer layer is a hydrophobic nerve conduit skeleton layer by the electrostatic spinning method; the cavity is used for storing a bioactive factor solution. The nerve conduit has the characteristics of being proper in strength and hardness, degradable, capable of providing proper neurotrophic active substances, ideal in double-layer or multi-layer structure, semi-permeable, low in cost, short in production cycle, easy to be stored and transported, free of viruses, free of immunological rejection or extremely small in immunological rejection, and wide in applicable scope; the requirement on nerve regeneration process can be met well.

Focal and segmental glomerulosclerosis (FSGS) is a kidney disorder of unknown etiology and up to 20% of patients on dialysis have this diagnosis. A large family with hereditary FSGS carries a missense mutation in the TRPC6 gene on chromosome 11q, encoding the ion channel protein Transient Receptor Potential Cation Channel 6. The missense mutation is a P112Q substitution, which occurs in a highly conserved region of the protein, enhances TRPC6-mediated calcium signals in response to agonists such as angiotensin II, and alters the intracellular distribution of TRPC6 protein. Previous work has emphasized the importance of cytoskeletal and structural proteins in proteinuric kidney diseases. Our findings suggest a novel mechanism for glomerular disease pathogenesis.

The invention provides an in-vitro brain-like tissue and an establishment method thereof, and solves the problem of a source of an in-vitro pathological and pharmacological human brain model. According to the establishment method, printing of various nerve cells and cytoskeletons is achieved in a 3D printing way, and single-layer or multi-layer brain-like tissue structures consisting of single cells or multi-cells of human brain cortex tissues, nucleus tissues and cortex and white matter tissues are established; by virtue of own advantages of 3D printing, precise control of the type, the density, the relative position and the like of printed cells can be achieved; through mutual matching of different printing heads, printing of functional nucleus brain-like tissues, cortical stratified brain-like tissues, cortex and white matter brain-like tissues and other multi-layer and multi-gradient structural tissues of various single cells can be achieved; the establishment method is easy to operate and high in efficiency, and is applicable to batch and personalized production; an established brain-like tissue model is closer to a natural brain tissue and provides a basic model for pathological and pharmacological experiments.

The present invention elates to the applications of neuregulin in the preparation of drugs for preventing, treating or delaying the ischemia-reperfusion injury (IRI) in mammals, particularly in humans. In particular, the present invention provides the neuregulin based compositions and methods for preventing, treating or delaying the myocardial ischemia-reperfusion injury. Specifically, although it has been shown in cytological experiments, animal studies and clinical trials that neuregulin can improve the cytoskeleton structure of myocytes and cardiac function, it is still unknown whether neuregulin has effects on the myocardial ischemia-reperfusion injury. The present invention proves that neuregulin reduces the infarction size in the rat IRI model, which indicates that neuregulin can be used for preventing, treating or delaying the myocardial ischemia-reperfusion injury

Methods for inhibiting cancer, scar formation, disrupting the cellular cytoskeleton, and conferring resistance from infection are disclosed. Such methods comprise the administration of oleuropein and/or the products of its hydrolysis in therapeutically effective amounts. To that end, a variety of pharmaceutical formulations and routes or administration are disclosed and may be utilized to treat a wide variety of diseases.

The invention provides a purpose for preparing supplementary reproduction medicine from the following raw material medicine in percentage by weight: 18 to 30 parts of radix rehmanniae preparata, 9 to 12 parts of dogwood, 8 to 16 parts of Chinese yam, 9 to 12 parts of fructus lycii, 8 to 16 parts of semen cuscutae and 8 to 16 parts of antler gum. The invention also provides a method for promoting ovarian ovum in vitro maturation. The method comprises the following steps that a, an immature ovarian ovum is taken; and b, the immature ovarian ovum is placed in M199 culture liquid, a microdrop method is adopted for culture for 24 hours, and a mature ovarian ovum is obtained, wherein 2 percent of medicine is contained in the culture liquid. The medicine can promote the growth and development of the immature ovarian ovum in vitro and mainly promotes the ovarian ovum core maturation, and in addition, the cytoskeleton abnormality probability of the mature ovarian ovum is not increased. The medicine can also generate the influence on the ovum passing capability of sperms, and the reliable basis is provided for clinically preventing and treating the male sperm dysfunction, improving the IVF (in vitro fertilization) success ratio and reducing the use rate of ICSI (intracytoplasmic sperm injection).

The invention provides a method of inhibiting vascular hyperpermeability in an animal in need thereof. The method comprises administering a vascular-hyperpermeability-inhibiting amount of a danazol compound to the animal. The invention also provides a method of modulating the cytoskeleton of an endothelial cell in an animal. The method comprises administering an effective amount of a danazol compound to the animal.